Superior anti-tumor protection and therapeutic efficacy of vaccination with allogeneic and semiallogeneic dendritic cell/tumor cell fusion hybrids for murine colon adenocarcinoma
/in Colorectal Cancer, International Publications /von 2006-11-28 / Cancer Immunol. Immunother. 2007 Jul;56(7):1025-36Vaccination of advanced prostate cancer patients with PSCA and PSA peptide-loaded dendritic cells induces DTH responses that correlate with superior overall survival
/in International Publications, Prostate Cancer /von 2006-11-15 / Int. J. Cancer 2006 Nov;119(10):2428-34Antigen-independent immune responses after dendritic cell vaccination
/in Hypernephroma, International Publications /von 2006-11-15 / Cancer Immunol. Immunother. 2007 Jun;56(6):897-903Hyperthermia and immunity. A brief overview
/in Hypernephroma, Hyperthermia, International Publications, Malignant Melanoma /von 2006-11-01 / In Vivo 2006 Nov-Dec;20(6A):689-95Hyperthermia combined with intra-thoracic chemotherapy and radiotherapy for malignant pleural mesothelioma
/in Hyperthermia, International Publications, Malignant Pleural Mesothelioma /von 2006-11-01 / Int J Hyperthermia 2006 Nov;22(7):613-21A phase II clinical study on relapsed malignant gliomas treated with electro-hyperthermia
/in Glioblastoma, Hyperthermia, International Publications /von 2006-11-01 / In Vivo 2006 Nov-Dec;20(6A):721-4Recent advances in immunotherapy for human glioma
/in Glioblastoma, International Publications /von 2006-11-01 / Curr Opin Oncol 2006 Nov;18(6):631-6Neurospheres enriched in cancer stem-like cells are highly effective in eliciting a dendritic cell-mediated immune response against malignant gliomas
/in Glioblastoma, International Publications /von 2006-11-01 / Cancer Res. 2006 Nov;66(21):10247-52Dendritic cell vaccination in patients with malignant gliomas: current status and future directions
/in Glioblastoma, International Publications, IOZK Veröffentlichungen /von 2006-11-01 / Neurosurgery 2006 Nov;59(5):988-99; discussioin 999-1000
IMMUN-ONKOLOGISCHES ZENTRUM KÖLN
Hohenstaufenring 30–32
50674 Köln | Deutschland
T: +49 (0)221 – 420 399 25
E-Mail: info@iozk.de
Hohenstaufenring 30–32
50674 Köln | Deutschland
T: +49 (0)221 – 420 399 25
E-Mail: info@iozk.de
Das IOZK
Die IOZK Immuntherapie
Aktuelles und Int. Publikationen
- Recent developments in targeting breast cancer stem cells (BCSCs): a descriptive review of therapeutic strategies and emerging therapies
- Neoantigen-targeted dendritic cell vaccination in lung cancer patients induces long-lived T cells exhibiting the full differentiation spectrum
- Individualized Multimodal Immunotherapy (IMI): Scientific Rationale and Clinical Experience from a Single Institution